Clinical observation study of 5-year survivals in patients with newly diagnosed acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) in Japan Adult Leukemia Study Group
Not Applicable
- Conditions
- Acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML)
- Registration Number
- JPRN-UMIN000008371
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6100
Inclusion Criteria
Not provided
Exclusion Criteria
Past history of chemotherapy or stem cell transplantation in the treatment of AML, MDS, or CMM
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1)AML patient 5-year survivals (2)MDS patient 5-year survivals (3)CMML patient 5-year survivals (4) Usage conditions and efficacy of new agents (lenalidomide and DNMT inhibitors) in MDS patients (5))Numbers of patients with AML, MDS, CMML by age group, sex and type of diseases (6)Feasibility of classification according to known prognostic factors in AML, MDS, CMML. (7)Comparison of survivals between patients enrolled in AML209 study and not enrolled. (8)Usage conditions and efficacy of new agents (DNMT inhibitors) in CMML patients
- Secondary Outcome Measures
Name Time Method (1)Efficacy of DNMT inhibitors in lower risk MDS (IPSS low/Int-1 risk) (2) Frequency of Erythropoiesis-stimulating agent (ESA) use.